Novated and Restated Technology License Agreement



 Exhibit 10.4 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
  
 NOVATED AND RESTATED 
  
 TECHNOLOGY LICENSE AGREEMENT 
  
  
 dated as of June 9, 2005 
  
  
 among 
  
  
 EXELIXIS, INC., 
  
  
 SYMPHONY EVOLUTION, INC. 
  
  
 and 
  
  
 SYMPHONY EVOLUTION HOLDINGS LLC 
  








 Table of Contents 
  

					
	 	 	 	  	Page


	 Article  1
	 	Definitions	  	1
			
	 Article  2
	 	Grant Of Rights	  	1
			
	              2.1.
	 	  Assignment	  	1
	              2.2.
	 	  License Grant	  	2
	              2.3.
	 	  Sublicense to Licensor	  	2
	              2.4.
	 	  Right to Sublicense	  	2
	              2.5.
	 	  Partial Reversion of License upon Licensor’s Exercise of Program Option or Discontinuation Option	  	3
	              2.6.
	 	  Reservation of Rights	  	3
	              2.7.
	 	  Regulatory Files	  	4
	              2.8.
	 	  Delivery of Materials	  	4
	              2.9.
	 	  License Opportunities	  	4
	              2.10.
	 	  Separate Third Party License for Discontinued Program	  	5
			
	 Article  3
	 	Sublicense To Certain Third Party Intellectual Property	  	6
			
	              3.1.
	 	  General	  	6
	              3.2.
	 	  Option to Acquire Sublicense	  	6
	              3.3.
	 	  Prosecution Fees	  	6
	              3.4.
	 	  Termination or Amendment of University Agreements	  	6
	              3.5.
	 	  No Conflicts	  	7
			
	 Article  4
	 	Intellectual Property	  	7
			
	              4.1.
	 	  Ownership	  	7
	              4.2.
	 	  Marking	  	7
	              4.3.
	 	  Prosecution and Maintenance	  	7
	              4.4.
	 	  Abandonment	  	8
	              4.5.
	 	  Infringement	  	8
	              4.6.
	 	  First Enforcement Right During Term	  	9
	              4.7.
	 	  Post-Term Enforcement	  	9
	              4.8.
	 	  Withdrawal of Enforcement	  	10
	              4.9.
	 	  Recoveries	  	10
	              4.10.
	 	  Third Party Rights	  	10
			
	 Article  5
	 	Representations And Warranties	  	10
			
	              5.1.
	 	  Representations and Warranties of Licensor	  	10
	              5.2.
	 	  Disclaimer and Acknowledgement	  	11
			
	 Article  6
	 	Indemnification And Limitation Of Liability	  	11
			
	              6.1.
	 	  Indemnity	  	11
	              6.2.
	 	  Notice of Claims	  	12
	              6.3.
	 	  Defense of Proceedings	  	13
	              6.4.
	 	  Settlement	  	14

  

 i 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 









					
	              6.5.
	 	  Limitation of Liability	  	14
	              6.6.
	 	  Insurance	  	14
			
	 Article  7
	 	Term And Termination	  	15
			
	              7.1.
	 	  Term	  	15
	              7.2.
	 	  Termination	  	15
	              7.3.
	 	  Survival	  	15
	              7.4.
	 	  Bankruptcy	  	15
			
	 Article  8
	 	Miscellaneous	  	15
			
	              8.1.
	 	  Notices	  	15
	              8.2.
	 	  Entire Agreement	  	16
	              8.3.
	 	  Assignment	  	16
	              8.4.
	 	  Headings	  	17
	              8.5.
	 	  Independent Contractor	  	17
	              8.6.
	 	  Severability	  	17
	              8.7.
	 	  No Third-Party Beneficiaries	  	17
	              8.8.
	 	  Compliance with Laws	  	17
	              8.9.
	 	  Amendment	  	17
	              8.10.
	 	  Governing Law; Consent to Jurisdiction and Service of Process	  	17
	              8.11.
	 	  Waiver Of Jury TriaL	  	18
	              8.12.
	 	  Counterparts	  	18
	              8.13.
	 	  No Waiver	  	18

  

 ii 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 NOVATED AND RESTATED 
 TECHNOLOGY LICENSE AGREEMENT 
  
 This NOVATED AND RESTATED TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made and effective as of June 9, 2005 (the “Effective Date”) by and among, Exelixis Inc., a Delaware corporation
(the “Licensor”), Symphony Evolution, Inc., a Delaware corporation (“Symphony Evolution”) (each of Licensor and Symphony Evolution being a “Party,” and collectively, the
“Parties”), and Symphony Evolution Holdings LLC, a Delaware limited liability company (“Holdings”). 
  
 WHEREAS, Licensor and Holdings have entered into that certain Technology License Agreement, dated June 9, 2005 (the “Original
Agreement”); 
  
 WHEREAS, Holdings desires to assign
its right, title and interest in, and delegate and novate its obligations under the Original Agreement to Symphony Evolution, and Licensor and Symphony Evolution desire to novate and restate the terms and conditions of the Original Agreement to
effect such novation; 
  
 WHEREAS, Licensor owns or has rights in
certain technology, know-how, patents and other intellectual property rights related to the design, development, manufacture and/or use of XL647, XL784, and XL999 and/or the Products; 
  
 WHEREAS, Licensor desires to grant to Symphony Evolution, and Symphony Evolution desires to acquire, the exclusive right to
use such technology, know-how, patents and other intellectual property rights to develop and commercialize Products on the terms and conditions of this Agreement; and 
  
 WHEREAS, Licensor desires to receive, and Symphony Evolution desires to grant to Licensor, the exclusive right to use such
technology, know-how, patents and other intellectual property rights to develop Products on behalf of Symphony Evolution on the terms and conditions of this Agreement. 
  
 NOW THEREFORE, in consideration of the mutual promises and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
  
 ARTICLE 1 
 DEFINITIONS 
  
 Capitalized terms used herein and not defined shall have the meanings
assigned to such terms in Annex A attached hereto. 
  
 ARTICLE 2 
 GRANT OF RIGHTS 
  
 2.1. Assignment. Holdings hereby assigns to Symphony Evolution all of its right, title and interest in and to the
Original Agreement. The Parties agree that from and after the Effective Date, all of the right, title, interest and obligations of Holdings under the Original Agreement will be assigned, novated and transferred to, and assumed by, Symphony
Evolution, as amended and restated by this Agreement. 
  

 1 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 2.2. License Grant. Subject to Sections 2.3, 2.4 and 2.6 below, Licensor hereby grants to Symphony
Evolution, subject to the terms and conditions of this Agreement, a fully paid, worldwide, exclusive (even as to Licensor) license under the Licensed Intellectual Property, to develop, make, have made, use, offer for sale, sell, and import XL647,
XL784, XL999 and Products. 
  
 2.3. Sublicense to Licensor.
Symphony Evolution hereby grants to Licensor a fully paid, worldwide, exclusive (even as to Symphony Evolution) sublicense under the Licensed Intellectual Property, with the right to grant further sublicense(s), to develop, make, have made, use and
import XL647, XL784, XL999 and Products, or otherwise as necessary or useful to carry out Licensor’s obligations or exercise Licensor’s rights under the Operative Documents. Notwithstanding the foregoing, Licensor shall only exercise its
sublicense rights in connection with and for the purpose of carrying out Licensor’s obligations or exercising Licensor’s rights under the Operative Documents. In the event of the expiration of a Discontinuation Option without exercise by
Licensor, the sublicense set forth in this Section 2.3 shall expire with respect to the compounds and Products relating to the Program to which such Discontinuation Option pertained. Upon expiration of the Term without Licensor’s exercise of
the Purchase Option, the sublicense set forth in this Section 2.3 shall expire with respect to all compounds and Products relating to the Program(s) for which Licensor has not exercised the Program Option or Discontinuation Option. 
  
 2.4. Right to Sublicense. The license granted hereunder includes the
right of Symphony Evolution to grant sublicenses under the Licensed Intellectual Property, provided, that, 
  
 (a) subject to Sections 2.3 and 2.4(b), Symphony Evolution shall not sublicense any of the rights granted pursuant to Section 2.2 to any third party
(including without limitation any Affiliates) during the Term; 
  
 (b) notwithstanding (a), in the event of the expiration of a Discontinuation Option without exercise by Licensor, Symphony Evolution may grant sublicense(s) to third parties (including without limitation Affiliates) of the rights granted
pursuant to Section 2.2 with respect to the compounds and Products relating to the Program to which such Discontinuation Option pertained, provided that Symphony Evolution acts in accordance with Section 11.2(b) of the Amended and Restated Research
and Development Agreement; 
  
 (c) each sublicense granted is (i)
pursuant to a written contract, (ii) consistent with the terms of this Agreement, (iii) does not grant any rights beyond the scope of the license rights granted herein, and (iv) is as protective of Licensor’s rights as set forth in this
Agreement; and 
  
 (d) upon Licensor’s written request,
Symphony Evolution shall provide to Licensor copies of any sublicense agreements, provided that (i) Symphony Evolution may redact any financial or other proprietary information contained therein which does not affect Licensor’s 
  

 2 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 rights and (ii) Licensor shall treat its copy of the sublicense agreements as Confidential Information of Symphony
Evolution, provided that, if Symphony Evolution exercises its option in Section 3.2, Licensor may disclose such sublicense agreement or the material terms thereof as necessary to fulfill its obligations under the Yale Agreement or Regents Agreement,
as applicable. 
  
 2.5. Partial Reversion of License upon
Licensor’s Exercise of Program Option or Discontinuation Option. Licensor and Symphony Evolution acknowledge that Licensor may exercise its Program Option pursuant to Section 11.1 of the Amended and Restated Research and Development
Agreement, or its Discontinuation Option pursuant to Section 11.2 of the Amended and Restated Research and Development Agreement. Upon the Program Option Closing Date or the Discontinuation Option Closing Date, as applicable, (i) the license set
forth in Section 2.2 (and the corresponding sublicense under Section 2.3) shall expire with respect to the compounds and Products relating to the Program for which Licensor exercised its Program Option or Discontinuation Option, as applicable, (ii)
those patents, know-how and enhancements that were previously part of the Licensed Intellectual Property and relate to such Program (including its compounds and Products) but not to the other Programs, shall be deleted from the relevant intellectual
property definitions, and accordingly, Symphony Evolution shall no longer be responsible for any obligations or costs (including royalties or fees to third parties, prosecution costs, maintenance costs and enforcement costs) with respect to such
patents, know-how and enhancements; and (iii) Symphony Evolution shall (a) at Licensor’s request and option, promptly return to Licensor or destroy all Tangible Materials relating solely to such Program; and (b) upon Licensor’s request,
provide Licensor a copy of any Tangible Materials which relate to such Program (but not solely to such Program). The Parties shall, as necessary, promptly amend this Agreement, in connection with the exercise and consummation of the Program Option
pursuant to Section 11.1 or the Discontinuation Option pursuant to Section 11.2 of the Amended and Restated Research and Development Agreement, to give Licensor all rights it needs to pursue the Program for which such option was exercised without
any obligation to or dependency on Symphony Evolution and to limit this Agreement to the other Programs. 
  
 2.6. Reservation of Rights. All rights not expressly granted to a Party hereunder shall remain the exclusive property of the other Party.
Notwithstanding the exclusivity of the license granted to Symphony Evolution in Section 2.2, Licensor retains the right to make and use XL647, XL784, XL999 and Structurally Related Compounds solely for Licensor’s research purposes. Symphony
Evolution covenants and agrees not to use or exploit the Licensed Intellectual Property outside of the scope of the licenses granted herein. Licensor covenants and agrees not to use or exploit the Licensed Intellectual Property in connection with
the development, manufacture, use, sale, or importation of XL647, XL784, XL999 or Products after the expiration of all sublicenses granted pursuant to Section 2.3; provided, however, that such covenant by Licensor shall not (a) apply to any Program
for which Licensor exercises a Program Option or Discontinuation Option or to any compounds or Products relating to such Program or (b) restrict Licensor’s ability to practice the retained rights specified in this Section 2.6. 
  

 3 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 2.7. Regulatory Files. 
  
 (a) Within a reasonable time after the expiration or termination of the Purchase Option without exercise by Licensor and as
of a date to be agreed upon by Licensor and Symphony Evolution, Licensor and Symphony Evolution shall, at Symphony Evolution’s expense, take all actions necessary to effect the assignment to Symphony Evolution or its designee of the sponsorship
to the Regulatory Files with respect to the Programs for which Licensor has not exercised its Program Option or Discontinuation Option. After such Regulatory Files are assigned to Symphony Evolution, Licensor shall have no further rights therein or
obligations thereunder. Licensor shall, at the reasonable request of Symphony Evolution and at Symphony Evolution’s expense, perform any acts that Symphony Evolution may reasonably deem necessary or desirable to evidence or confirm Symphony
Evolution’s ownership interest in such Regulatory Files, including, but not limited to, making further written assignments in a form determined by Symphony Evolution. Without limiting the license rights granted under this ARTICLE 2, the Parties
understand and agree that the assignment of such Regulatory Files does not include an assignment of any Licensed Intellectual Property. 
  
 (b) In the event of the expiration of a Discontinuation Option without exercise by Licensor, the provisions of Section 2.7(a) shall apply solely with
respect to the Regulatory Files for the Program to which the Discontinuation Option pertained. 
  
 2.8. Delivery of Materials. 
  
 (a) Upon the expiration or termination of the Purchase Option without exercise by Licensor, Licensor shall, at Symphony Evolution’s expense, promptly deliver to Symphony Evolution all copies of Tangible Materials existing as of the
date of such expiration or termination that relate to the Programs for which Licensor has not exercised its Program Option or Discontinuation Option; provided, however that Licensor may also retain copies of (and the right to use) those Tangible
Materials that are required to be delivered to Symphony Evolution hereunder but which also relate to (i) any Program for which Licensor has exercised its Program Option or Discontinuation Option or (ii) any other product of Licensor. 
  
 (b) In the event of the expiration of a Discontinuation Option without
exercise by Licensor, Licensor shall, at Symphony Evolution’s expense, promptly deliver to Symphony Evolution all copies of Tangible Materials existing as of the date of such expiration that relate to the Program to which the Discontinuation
Option pertained; provided, however that Licensor may also retain copies of (and the right to use) those Tangible Materials that are required to be delivered to Symphony Evolution hereunder but which also relate to any other Program or any other
product of Licensor. 
  
 2.9. License Opportunities. In the
event that, during the Term, Licensor reasonably determines that it is necessary to license from any third party any intellectual property relating to the composition of matter, use, manufacture, formulation or exploitation of XL647, XL784, or XL999
or the Products (“Third Party IP”) and Licensor desires to license such Third Party IP during the Term, then (i) if Licensor desires Symphony Evolution to pay any or all of the financial obligations under such license,
Licensor shall obtain Symphony Evolution’s written consent, which shall not be unreasonably withheld or delayed 
  

 4 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 before acquiring such license; and (ii) if Symphony Evolution provides such consent, then unless otherwise agreed to by
the Parties in writing, Licensor shall use commercially reasonable efforts to obtain, at the time such license is granted, the right to sublicense such Third Party IP to Symphony Evolution consistent with the terms of this Agreement as if such Third
Party IP were Licensed Intellectual Property. Unless otherwise agreed to by the Parties in writing, the financial obligations under any licenses to Third Party IP obtained by Licensor with Symphony Evolution’s consent shall (1) be borne fully
by Symphony Evolution if such Third Party IP relates solely to the composition of matter, use, manufacture, formulation or exploitation of XL647, XL784, or XL999 or the Products and, at the time of entering into such third party license, Licensor
has not exercised its Program Option or Discontinuation Option with respect to the Program to which such Third Party IP relates; or (2) be shared by the Parties in amounts and/or percentages to be agreed upon by the Parties prior to Licensor
entering into such third party license, if such Third Party IP relates (but does not relate solely) to the composition of matter, use, manufacture, formulation or exploitation of Products within Program(s) for which Licensor has not exercised its
Program Option and/or Discontinuation Option and also relates to either (x) the composition of matter, use, manufacture, formulation or exploitation of Products within Program(s) for which Licensor has exercised its Program Option and/or
Discontinuation Option or (y) the composition of matter, use, manufacture, formulation or exploitation of other products of Licensor; or (3) be borne fully by Licensor if such Third Party IP relates solely to the composition of matter, use,
manufacture, formulation or exploitation of a Product(s) within a Program(s) for which Licensor has exercised its Program Option and/or Discontinuation Option. Notwithstanding the foregoing, Licensor shall have no obligation to obtain any such third
party licenses under this Agreement or, in the event that Symphony Evolution does not give such consent, to grant any sublicenses to Symphony Evolution. Upon obtaining a license to such Third Party IP and the right to sublicense to Symphony
Evolution, the Parties will, as necessary, promptly amend this Agreement to include such sublicensed intellectual property within the license granted hereunder, incorporate any other limitations, royalties or other provisions required by such third
party with respect to such sublicense, and address Symphony Evolution’s rights (if any) with respect to patent prosecution, maintenance and enforcement of patents and patent applications within such Third Party IP. 
  
 2.10. Separate Third Party License for Discontinued Program. In the
event of the expiration of a Discontinuation Option without exercise by Licensor, Symphony Evolution has the right to transfer to a third party, in accordance with Section 11.2(b) of the Amended and Restated Research and Development Agreement,
Symphony Evolution’s rights to the compounds and Products relating to the Program to which such Discontinuation Option pertained (the “Discontinued Program”). If Symphony Evolution identifies a third party that wishes to
obtain such rights, then upon Symphony Evolution’s request, (i) Licensor and Symphony shall amend this Agreement to terminate all of Symphony Evolution’s rights and obligations to the extent applicable to the Discontinued Program and (ii)
Licensor shall enter into a separate license agreement with such third party in which all of such terminated rights and obligations shall be conferred upon and undertaken by such third party. The terms and conditions of such license agreement shall
be identical to those contained herein, to the extent that such terms are applicable to the Discontinued Program and not dependent on any Operative Document other than this Agreement. Such terms shall include but not be limited to (1) provisions
allowing for termination of such license agreement upon a material, uncured breach of such license agreement by the third party on similar terms as provided herein with respect to 
  

 5 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 Symphony Evolution and (2) a confidentiality provision that is not dependent on any of the Operative Documents.
Termination of this Agreement shall not effect such license agreement and Licensor’s obligation to enter into such a license agreement shall survive termination of this Agreement. 
  
 ARTICLE 3 
 SUBLICENSE TO CERTAIN THIRD PARTY INTELLECTUAL PROPERTY 
  
 3.1. General. The Parties acknowledge and agree that the license set forth in Section 2.2 does not include certain Intellectual Property (the “University IP”) which has been in-licensed
by Licensor from Yale University (“Yale”) pursuant to the Yale Exclusive License Agreement between Licensor and Yale effective January 9, 2002 (the “Yale Agreement”) and the Regents of the University
of California (“Regents”) pursuant to the Exclusive License and Bailment Agreement between Licensor and Regents effective July 25, 2001 (the “Regents Agreement” and together with the Yale Agreement,
the “University Agreements”). 
  
 3.2.
Option to Acquire Sublicense. In the event of (i) an expiration of a Discontinuation Option in respect of the Program relating to XL784 without exercise by Licensor or (ii) an expiration of the Purchase Option without exercise by Licensor
(and Licensor has not exercised a Discontinuation Option or Program Option in respect of the Program relating to XL784), then, upon Symphony Evolution’s written request, the Parties shall amend this Agreement to provide that, effective upon
such expiration of the Discontinuation Option or Purchase Option (as applicable), Symphony Evolution is granted a sublicense in and to such University IP to develop, make, have made, use, offer for sale, sell, and import XL784 and related Products;
provided, however, that, with respect to the Intellectual Property licensed under the Yale Agreement, Symphony Evolution’s sublicense shall be limited to Licensed Products as defined in the Yale Agreement, and, with respect to the
Intellectual Property licensed under the Regents Agreement, Symphony Evolution’s sublicense shall be limited to Licensed Products as defined in the Regents Agreement. The terms and conditions of the sublicense shall be consistent with and no
broader than the terms and conditions contained herein with respect to Licensed Intellectual Property; provided, however, such sublicense shall contain such additional terms and obligations as are required under the University
Agreements, including all terms set forth in Annex C. Without limiting Licensor’s obligations under Section 3.4, the option set forth in this Section 3.2 shall expire with respect to the Yale Agreement and the Regents Agreement upon the
expiration or termination of the Yale Agreement and the Regents Agreement, respectively. 
  
 3.3. Prosecution Fees. Symphony Evolution shall reimburse Licensor, within [ * ] after receipt of Licensor’s invoice, for [ * ] of the costs incurred by Licensor with respect to the filing,
prosecution and maintenance of all patent applications and patents included within the University IP. The foregoing obligation of Symphony Evolution shall terminate upon any exercise by Licensor of a Program Option or Discontinuation Option in
respect of the Program related to XL784. 
  
 3.4. Termination
or Amendment of University Agreements. Licensor may not (a) terminate any University Agreements or (b) amend any University Agreements in a 
  

 6 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 manner that would conflict with or otherwise limit Licensor’s obligations to Symphony Evolution under Section 3.2
without (i) giving Symphony Evolution reasonable advance written notice of such intention and (ii) in the event that Yale or Regents agree to (1) permit the Yale Agreement or the Regents Agreement, respectively, to be assigned to Symphony Evolution
or to (2) grant a substitute license to the relevant University IP to Symphony Evolution, executing any document necessary to effect such assignment or permit such substitute license and, in the event that Licensor terminates both the Yale Agreement
and the Regents Agreement, transferring to Symphony Evolution any applicable patent files in respect of the University IP (provided that the foregoing shall not be construed to require Licensor to pay any amounts or to undertake any additional
obligations). 
  
 3.5. No Conflicts. Licensor shall not
enter into any agreements with third parties that would conflict with or otherwise limit Licensor’s obligations to Symphony Evolution under Section 3.2. 
  
 ARTICLE 4 
 INTELLECTUAL
PROPERTY 
  
 4.1. Ownership. The Parties
acknowledge and agree that, as between Licensor and Symphony Evolution, Licensor or its licensors are the owner of all right, title and interest in and to the Licensed Intellectual Property, including without limitation Symphony Evolution
Enhancements. Symphony hereby assigns to Licensor all of Symphony Evolution’s rights and interests in any Symphony Evolution Enhancements. Symphony Evolution shall promptly disclose any Symphony Evolution Enhancement to Licensor, and shall use
reasonable efforts, at Licensor’s request and at no cost to Licensor, to cooperate fully with Licensor to transfer such Symphony Evolution Enhancements to Licensor. 
  
 4.2. Marking. Symphony Evolution shall mark, and shall cause all of its sublicensees to mark, all Products, or the
packaging thereof or materials related thereto, with the number of the applicable patents licensed hereunder in accordance with applicable U.S. patent law. 
  
 4.3. Prosecution and Maintenance. 
  
 (a) Unless otherwise set forth in this Section 4.3, (i) Licensor shall prepare, file, prosecute and maintain, in the name of Licensor, those patents and
patent applications in Licensed Patent Rights for which, as between Licensor and Third Party Licensors, Licensor has patent prosecution and maintenance rights at such time; and (ii) Licensor shall provide Symphony Evolution with (1) quarterly
reports regarding the status of the prosecution and maintenance of such patents and patent applications, (2) copies of any patent documents provided to GlaxoSmithKline with respect to such patents and patent applications, and (3) timely answers to
Symphony Evolution’s questions regarding the status of patents and patent applications in Licensed Patent Rights. 
  
 (b) Licensor will use commercially reasonable efforts to seek the allowance of broad generic claims, consistent with Licensor’s determination of
enforceability, business considerations and other factors. 
  

 7 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 (c) Subject to any such costs paid by Third Party Licensors, the cost of such prosecution and maintenance
of Licensed Patent Rights shall be paid by Symphony Evolution. Upon the scope of any Licensed Patent Rights being amended so that the patent or patent application’s claims no longer relate to XL647, XL784, XL999 or any Products, such patent or
patent application shall cease to be a Licensed Patent Right and all rights and obligations with respect to such patent or patent application (including costs, fees, prosecution, maintenance and enforcement) shall revert to Licensor. 
  
 (d) Symphony Evolution shall not be responsible for the costs of any
interference or reexamination initiated by Licensor with respect to the Licensed Patent Rights (except to the extent allocated in the Development Budget), unless the Parties mutually agree in writing that it is reasonably necessary or useful to file
and prosecute such interference or re-examination in connection with such Licensed Patent Rights to protect their interests in such Licensed Patent Rights, which agreement will not be unreasonably withheld or delayed. In the event of such agreement,
unless otherwise agreed in writing by the Parties, Symphony Evolution shall pay all costs of such interference or reexamination. 
  
 (e) Each Party shall provide the prosecuting Party with reasonable cooperation under this Section 4.3. 
  
 (f) Symphony Evolution acknowledges that Licensor has certain obligations to
GlaxoSmithKline with respect to the prosecution and maintenance of certain patents and patent applications within the Licensed Patent Rights, including without limitation certain obligations to [ * ]. Nothing in this Agreement shall be
interpreted as requiring Licensor to breach such obligations to GlaxoSmithKline. Notwithstanding the foregoing, Licensor shall use commercially reasonable efforts to make, no later than upon any expiration of the Term without Licensor’s
exercise of the Purchase Option, any amendment to the GSK Agreement (as defined in Section 4.10) that may be necessary to provide that, upon any such expiration of the Term, GlaxoSmithKline shall no longer have any rights with respect to [ *
]. 
  
 4.4. Abandonment. The Parties acknowledge that
in the event Licensor desires to abandon any patent or patent application covering Licensed Patent Rights (whether during or after the Term), Licensor shall provide prompt, timely written notice thereof to Symphony Evolution. If Symphony Evolution
informs Licensor in writing at least [ * ] before the relevant deadline that Symphony Evolution desires to avoid such abandonment or lapse, then Licensor shall continue to prosecute or maintain such patent or patent application at Symphony
Evolution’s request and sole expense. Symphony Evolution understands and acknowledges that Licensor cannot allow certain patents or patent applications in the Licensed Patent Rights to lapse or become abandoned without [ * ]. Nothing in
this Section 4.4 shall be interpreted as giving Symphony Evolution rights that conflict with such Licensor obligations. 
  
 4.5. Infringement. Each Party agrees to immediately notify the other Party upon becoming aware of any infringement, misappropriation, illegal use
or misuse of the Licensed Intellectual Property and provide to the other party all available evidence of such infringement. 
  

 8 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 4.6. First Enforcement Right During Term. During the Term, as between the Parties, Licensor has
the first right, but not the obligation, to take action against others in the courts, administrative agencies or otherwise, at Symphony Evolution’s cost and expense, to prevent or terminate infringement, misappropriation, illegal use or misuse
of the Licensed Patent Rights or other Licensed Intellectual Property due to the manufacture, use or sale of a product or compound that might be competitive with a Product. Symphony Evolution shall, at its expense, cooperate with and reasonably
assist Licensor in any such action if so requested by Licensor, and, upon Licensor’s request, execute, file and deliver all documents and proof necessary for such purpose, including being named as a party to such litigation if requested by
Licensor or if required by law. Subject to Section 4.10, Symphony Evolution shall have the right to participate and be represented by its own counsel at its own expense in any such action, suit or proceeding with respect to Licensed Patent Rights
solely relating to Products for which Licensor has not exercised its Program Option or Discontinuation Option. Subject to Section 4.10, Licensor shall not enter into any settlement or compromise of such action, suit or proceeding that affects or
concerns the validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property without the prior written consent of Symphony Evolution, which consent shall not be unreasonably withheld or delayed.

  
 4.7. Post-Term Enforcement. 
  
 (a) Following the expiration of the Term without Licensor’s exercise of
the Purchase Option, as between the Parties, Symphony Evolution shall have the first right, but not the obligation, to take action against others in the courts, administrative agencies or otherwise, under Symphony Evolution’s direction and
control and at Symphony Evolution’s cost and expense, to prevent or terminate infringement, misappropriation, illegal use or misuse of any Licensed Patent Rights or other Licensed Intellectual Property that solely relate to a Product for which
Licensor has not exercised its Program Option or Discontinuation Option, due to the manufacture, use or sale of a product or compound that might be competitive with such Product. Licensor shall, at Symphony Evolution’s expense, cooperate and
reasonably assist Symphony Evolution in such action if so requested, and upon Symphony Evolution’s request, execute, file and deliver all documents and proof necessary for such purpose, including being named as a party to such litigation if
requested by Symphony Evolution or if required by law. Licensor shall have the right to participate and be represented in any such action, suit or proceeding by its own counsel at its own expense. Symphony Evolution shall not enter into any
settlement or compromise of such action, suit or proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property without the prior written consent of Licensor,
which consent shall not be unreasonably withheld or delayed. 
  
 (b) Following the expiration of the Term without Licensor’s exercise of the Purchase Option, if Symphony Evolution does not take action under Section 4.7(a) within [ * ] of Licensor’s written request that Symphony Evolution
take such action, then Licensor shall have the option to commence any such action under its own direction and control, and at Licensor’s cost and expense. Symphony Evolution shall, at Licensor’s expense, cooperate and reasonably assist
Licensor in such action if so requested, and upon Licensor’s request, execute, file and deliver all documents and proof necessary for such purpose, including being named as a party to such litigation if requested by Licensor or if required by
law. Symphony Evolution shall have 
  

 9 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 the right to participate and be represented in any such action, suit or proceeding by its own counsel at its own expense.
Licensor shall not enter into any settlement or compromise of such action, suit or proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property without the prior
written consent of Symphony Evolution, which consent shall not be unreasonably withheld or delayed. 
  
 4.8. Withdrawal of Enforcement. If either Party brings an action under this ARTICLE 4 and subsequently ceases to pursue or withdraws from such
action, it shall promptly notify the other Party and the other Party may substitute itself for the withdrawing party under the terms of this ARTICLE 4, provided that such substitution would not constitute a breach of Licensor’s obligations to
any Third Party Licensor. 
  
 4.9. Recoveries. All damages
or other compensation of any kind recovered in such action, suit, or proceeding or from any settlement or compromise brought under this ARTICLE 4 shall first be used to reimburse each Party for its expenses in connection with such action, suit or
proceeding, (in proportion to the expenses of each Party if recovery is insufficient to cover all such expenses) and the remainder of such recovery, after Licensor makes any other payments it is obligated to make to Third Party Licensors on account
of such recovery, shall be allocated [ * ]. 
  
 4.10.
Third Party Rights. Symphony Evolution acknowledges that Licensor has certain obligations to GlaxoSmithKline with respect to the enforcement of certain patents and patent applications within the Licensed Patent Rights, including without
limitation [ * ]. Nothing in this Agreement shall be interpreted as requiring Licensor to breach such obligations to GlaxoSmithKline. Notwithstanding the foregoing, (i) in the event that GlaxoSmithKline exercises its option to [ * ]
the Product Development and Commercialization Agreement between Licensor and GlaxoSmithKline dated October 28, 2002 (the “GSK Agreement”), Licensor shall use commercially reasonable efforts to amend the GSK Agreement as soon
as reasonably practical after such exercise but in no event later than any expiration of the Term without Licensor’s exercise of the Purchase Option, to provide that upon any expiration of the Term without Licensor’s exercise of the
Purchase Option, GlaxoSmithKline shall no longer have any right to [ * ]; and (ii) in the event GlaxoSmithKline does not exercise its option to [ * ], Licensor hereby represents and warrants to Symphony Evolution that upon expiration
of the Term pursuant to Section 1(c)(iii)(x) of the Purchase Option Agreement, GlaxoSmithKline shall no longer have any right to [ * ]. 
  
 ARTICLE 5 
 REPRESENTATIONS AND
WARRANTIES 
  
 5.1. Representations and Warranties of
Licensor. Licensor hereby represents and warrants to Symphony Evolution, that, as of the Effective Date: 
  
 (a) Licensor is the owner of all right, title, and interest in and to (i) all Licensed Patent Rights listed in Annex B and not identified as jointly owned
or licensed from a third party and (ii) the Regulatory Files; 
  

 10 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 (b) Licensor has sufficient rights to grant the licenses granted hereunder and the grant of such licenses
does not and will not conflict with any agreement to which Licensor is a party or otherwise governing the Licensed Intellectual Property; 
  
 (c) To the Knowledge of Licensor, no third party is engaging in any activity that infringes or misappropriates the Licensed Intellectual Property;

  
 (d) No element of the Licensed Intellectual Property has been
adjudged invalid or unenforceable in whole or part, and to the Knowledge of Licensor, the issued patents within the Licensed Intellectual Property are valid and enforceable; 
  
 (e) To the Knowledge of Licensor, no actions or claims have been asserted, are pending or have been threatened, against
Licensor in writing alleging that the manufacture, use or sale of XL647, XL784 or XL999 misappropriates or infringes the intellectual property rights of any third party; and 
  
 (f) To the Knowledge of Licensor, the manufacture, use or sale of XL647, XL784 or XL999 by Symphony Evolution (or its
sublicensees) in strict accordance with the licenses herein and other terms of this Agreement will not misappropriate or infringe the intellectual property rights of any third party. 
  
 5.2. Disclaimer and Acknowledgement. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 5, THE LICENSED INTELLECTUAL
PROPERTY, PRODUCTS (AND THE COMPOUNDS THEREIN), TANGIBLE MATERIALS AND REGULATORY FILES ARE PROVIDED “AS IS” WITH NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, AND LICENSOR EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT. LICENSOR DOES NOT WARRANT THE PERFORMANCE OF ANY PRODUCT (OR THE COMPOUND(S) THEREIN), INCLUDING THEIR SAFETY, EFFECTIVENESS OR
COMMERCIAL VIABILITY. ANY SYMPHONY EVOLUTION ENHANCEMENTS PROVIDED TO LICENSOR HEREUNDER ARE PROVIDED “AS IS” WITH NO REPRESENTATIONS OR WARRANTIES OF ANY KIND AND SYMPHONY EVOLUTION EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT. 
  
 ARTICLE 6 
 INDEMNIFICATION AND LIMITATION OF LIABILITY 

 
 6.1. Indemnity. To the greatest extent permitted by applicable law,
Licensor shall indemnify and hold harmless Symphony Evolution, its Affiliates, and each of their respective officers, directors, employees, agents, members, managers, successors and assigns (each, a “Symphony Evolution Indemnified
Party”) and Symphony Evolution shall indemnify and hold harmless Licensor, its Affiliates and each of their respective officers, directors, employees, agents, members, successors and assigns (each, an “Exelixis Indemnified
Party” and together with Symphony Evolution Indemnified Party, the “Indemnified Parties”), from and 
  

 11 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 against any and all claims, losses, diminution in value, costs, interest, awards, judgments, penalties, fees (including
reasonable fees for attorneys and other professionals), court costs, liabilities, damages and expenses incurred by any Symphony Evolution Indemnified Party or Exelixis Indemnified Party (irrespective of whether any such Symphony Evolution
Indemnified Party or Exelixis Indemnified Party, as applicable, is a party to the action for which indemnification hereunder is sought), (collectively, a “Loss”) as a result of, arising out of, or relating to any and all
third party suits, claims, actions, proceedings, investigations, litigation or demands based upon: 
  
 (i) in the case of Licensor being the Indemnifying Party, (A) any breach of any representation or warranty made by Licensor herein or in
any certificate, instrument or document delivered hereunder, (B) any breach of any covenant, agreement or obligation of Licensor contained herein, or in any certificate, instrument or document delivered hereunder, or (C) any act of gross negligence
or willful misconduct by Licensor in performing its obligations under this Agreement; in each case, except (1) with respect to Losses for which Licensor is entitled to indemnification under this ARTICLE 6 or (2) to the extent such Loss arises from
the gross negligence or willful misconduct of a Symphony Evolution Indemnified Party, and 
  
 (ii) in the case of Symphony Evolution being the Indemnifying Party, (A) any breach of any representation or warranty made by Symphony
Evolution herein or in any certificate, instrument or document delivered hereunder, (B) any breach of any covenant, agreement or obligation of Symphony Evolution contained herein, or in any certificate, instrument or document delivered hereunder,
(C) any act of gross negligence or willful misconduct by Symphony Evolution in performing its obligations under this Agreement, or (D) the development, manufacture, use, handling, storage, sale or other disposition of the Product (other than those
Products arising from a Program for which Licensor exercised a Program Option or Discontinuation Option) after end of the Term; in each case, except (1) with respect to Losses for which Symphony Evolution is entitled to indemnification under this
ARTICLE 6 or (2) to the extent such Loss arises from the gross negligence or willful misconduct of an Exelixis Indemnified Party. 
  
 To the extent that the foregoing undertakings by Licensor and/or Symphony Evolution may be unenforceable for any reason, such Party shall make the maximum
contribution to the payment and satisfaction of any Loss that is permissible under applicable Law. 
  
 6.2. Notice of Claims. Any Indemnified Party that proposes to assert a right to be indemnified under this ARTICLE 6 shall notify Licensor or
Symphony Evolution, as applicable (the “Indemnifying Party”), promptly after receipt of notice of commencement of any action, suit or proceeding against such Indemnified Party (an “Indemnified
Proceeding”) in respect of which a claim is to be made under this ARTICLE 6, or the incurrence or realization of any Loss in respect of which a claim is to be made under this ARTICLE 6, of the commencement of such Indemnified Proceeding
or of such incurrence or realization, enclosing a copy of all relevant documents, including all papers served and claims made, but the omission so to notify the applicable Indemnifying Party promptly of any such Indemnified Proceeding or incurrence
or realization shall not relieve (a) such Indemnifying Party from any liability that it may have to such Indemnified Party under this ARTICLE 6 or otherwise, except, as to such 
  

 12 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 Indemnifying Party’s liability under this ARTICLE 6, to the extent, but only to the extent, that such Indemnifying
Party shall have been prejudiced by such omission, or (b) any other indemnitor from liability that it may have to any Indemnified Party under the Operative Documents. 
  
 6.3. Defense of Proceedings. In case any Indemnified Proceeding shall be brought against any Indemnified Party, it
shall notify the applicable Indemnifying Party of the commencement thereof and such Indemnifying Party shall be entitled to participate in, and provided such Indemnified Proceeding involves a claim solely for money damages and does not seek an
injunction or other equitable relief against the Indemnified Party and is not a criminal or regulatory action, to assume the defense of, such Indemnified Proceeding with counsel reasonably satisfactory to such Indemnified Party, and after notice
from such Indemnifying Party to such Indemnified Party of such Indemnifying Party’s election so to assume the defense thereof and the failure by such Indemnified Party to object to such counsel within [ * ] following its receipt of such
notice, such Indemnifying Party shall not be liable to such Indemnified Party for legal or other expenses related to such Indemnified Proceedings incurred after such notice of election to assume such defense except as provided below and except for
the reasonable costs of investigating, monitoring or cooperating in such defense subsequently incurred by such Indemnified Party reasonably necessary in connection with the defense thereof. Such Indemnified Party shall have the right to employ its
counsel in any such Indemnified Proceeding, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party unless: 
  
 (a) the employment of counsel by such Indemnified Party at the expense of the applicable Indemnifying Party has been authorized in writing by such
Indemnifying Party; 
  
 (b) such Indemnified Party shall have
reasonably concluded in its good faith (which conclusion shall be determinative unless a court determines that such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between the applicable
Indemnifying Party and such Indemnified Party in the conduct of the defense of such Indemnified Proceeding or that there are or may be one or more different or additional defenses, claims, counterclaims, or causes of action available to such
Indemnified Party (it being agreed that in any case referred to in this clause (b) such Indemnifying Party shall not have the right to direct the defense of such Indemnified Proceeding on behalf of the Indemnified Party); 
  
 (c) the applicable Indemnifying Party shall not have employed counsel
reasonably acceptable to the Indemnified Party, to assume the defense of such Indemnified Proceeding within a reasonable time after notice of the commencement thereof (provided, however, that this clause shall not be deemed to constitute a
waiver of any conflict of interest that may arise with respect to any such counsel); or 
  
 (d) any counsel employed by the applicable Indemnifying Party shall fail to timely commence or diligently conduct the defense of such Indemnified Proceeding; 
  
 in each of which cases the fees and expenses of counsel for such Indemnified
Party shall be at the expense of such Indemnifying Party. Only one counsel shall be retained by all Indemnified Parties with respect to any Indemnified Proceeding, unless counsel for any 
  

 13 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 Indemnified Party reasonably concludes in good faith (which conclusion shall be determinative unless a court determines
that such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of interest between such Indemnified Party and one or more other Indemnified Parties in the conduct of the defense of such Indemnified Proceeding
or that there are or may be one or more different or additional defenses, claims, counterclaims, or causes or action available to such Indemnified Party. 
  
 6.4. Settlement. Without the prior written consent of such Indemnified Party, such Indemnifying Party shall not settle or compromise, or consent to
the entry of any judgment in, any pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or related judgment (i) includes an unconditional release of such Indemnified Party from all liability for Losses arising out
of such claim, action, investigation, suit or other legal proceeding, (ii) provides for the payment of money damages as the sole relief for the claimant (whether at law or in equity), (iii) involves no finding or admission of any violation of law or
the rights of any Person by the Indemnified Party, and (iv) is not in the nature of a criminal or regulatory action. No Indemnified Party shall settle or compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified
Proceeding in respect of which any payment would result hereunder or under the Operative Documents without the prior written consent of the Indemnifying Party, such consent not to be unreasonably conditioned, withheld or delayed. 
  
 6.5. Limitation of Liability. TO THE GREATEST EXTENT PERMITTED BY
APPLICABLE LAW, NEITHER PARTY NOR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, MEMBERS, MANAGERS, EMPLOYEES, INDEPENDENT CONTRACTORS OR AGENTS SHALL HAVE ANY LIABILITY OF ANY TYPE (INCLUDING, BUT NOT LIMITED TO, CLAIMS IN CONTRACT, NEGLIGENCE AND
TORT LIABILITY) FOR ANY SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, THE LOSS OF OPPORTUNITY, LOSS OF USE OR LOSS OF REVENUE OR PROFIT IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR THE
SERVICES PERFORMED HEREUNDER, EVEN IF SUCH DAMAGES MAY HAVE BEEN FORESEEABLE. THE FOREGOING SHALL NOT LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO SECTION 6.1. 
  
 6.6. Insurance. Each Party shall maintain insurance, including on the part of Symphony Evolution, product liability
insurance, with respect to its activities under this Agreement. Such insurance shall be in such amounts and subject to such deductibles as are prevailing in the industry from time to time. Symphony Evolution shall maintain a minimum of an aggregate
of $10,000,000 in directors and officers insurance and an aggregate of $10,000,000 in product liability insurance. Notwithstanding anything to the contrary herein, this Section 6.6 shall survive only for a period of two (2) years following
termination or expiration of this Agreement. 
  

 14 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 ARTICLE 7 
 TERM AND TERMINATION 
  
 7.1. Term. This Agreement shall commence on the Effective Date and shall remain in force until terminated as provided herein. 
  
 7.2. Termination. 
  
 (a) Either Party may terminate this Agreement at any time if the other Party is in material default or breach of this Agreement that has resulted in, or
would reasonably be expected to result in, a material adverse effect on the Programs or the non-breaching Party’s rights under the Operative Documents, and such material default or breach continues unremedied for a period of [ * ] after
written notice thereof is delivered to the defaulting or breaching party. 
  
 (b) Licensor may terminate this Agreement at any time upon written notice to Symphony Evolution if (i) Investors materially breaches Sections 2 or 3 of the Funding Agreement, (ii) Holdings breaches Section 2 of the
Subscription Agreement or (iii) Holdings or Symphony Evolution is in material default or breach the Purchase Option Agreement that has resulted in, or would reasonably be expected to result in, a material adverse effect on the Licensor’s rights
under the Operative Documents and such default or breach is not cured within [ * ] after written notice of such default or breach under the Purchase Option Agreement is delivered to the defaulting or breaching party. 
  
 (c) Licensor may terminate this Agreement in the event that the Amended and
Restated Research and Development Agreement is terminated by Licensor in accordance with the terms thereof due to a material breach or default by Symphony Evolution or Holdings (without limiting any rights to notice or cure that Symphony Evolution
or Holdings may have under such agreements). 
  
 (d) Upon any
termination of this Agreement, all license rights granted herein (except for those rights granted in or pursuant to Section 2.5) shall immediately terminate. 
  
 7.3. Survival. The following Sections and Articles shall survive any expiration or termination of this Agreement: Sections 2.10, 4.1, 5.2 and 7.3,
and Articles 6 and 8. 
  
 7.4. Bankruptcy. All rights and
licenses granted under this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the “Code”), licenses to “Intellectual Property” as defined in the
Code. The Parties agree that each Party shall retain and may fully exercise all of its rights and elections under the Code. 
  
 ARTICLE 8 
 MISCELLANEOUS

  
 8.1. Notices. Any notice, request, demand, waiver,
consent, approval or other communication which is required or permitted to be given to any Party shall be in writing and shall be deemed given only if delivered to the Party personally or sent to the Party by 
  

 15 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 facsimile transmission (promptly followed by a hard-copy delivered in accordance with this Section 8.1), by next Business
Day delivery by a nationally recognized courier service, or by registered or certified mail (return receipt requested), with postage and registration or certification fees thereon prepaid, addressed to the Party at its address set forth below:

  
 Licensor: 
  
 Exelixis, Inc. 
 170 Harbor Way 
 South San Francisco, CA 94083 
 Attention: Corporate Secretary 
 Facsimile: (650) 837-7951 
  
 Symphony Evolution: 
  
 Symphony Evolution, Inc. 
 7361 Calhoun Place, Suite 325 
 Rockville, MD 20850 
 Attn: Charles Finn 
 Facsimile: (301) 762-6154 
  
 with a copy
to: 
  
 Symphony Capital Partners, L.P.

 875 Third Avenue 
 18th Floor 
 New York, NY 10022 
 Attn: Mark Kessel 
 Facsimile: (212) 632-5401 
  
 or to such other address as such Party may
from time to time specify by notice given in the manner provided herein to each other Party entitled to receive notice hereunder. 
  
 8.2. Entire Agreement. This Agreement (including any Annexes, Schedules, Exhibits or other attachments hereto) and the agreements referred to
herein (including the Operative Documents) constitute the entire agreement between the Parties with respect to the subject matter hereof, and no oral or written statement may be used to interpret or vary the meaning of the terms and conditions
hereof. This Agreement supersedes any prior or contemporaneous agreements and understandings, whether written or oral, between the Parties with respect to the subject matter hereof, including the Original Agreement but excluding the Operative
Documents. 
  
 8.3. Assignment. Neither Party may assign or
otherwise transfer this Agreement without the prior written consent of the other Party; provided, however, that (i) Licensor may assign this Agreement or any of its rights and obligations hereunder without the consent of Symphony Evolution
(A) to an Affiliate or in connection with a merger or the sale of all or substantially all of the assets of the Licensor to which this Agreement relates, or (B) to the 
  

 16 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 Surviving Entity in the event Licensor undergoes a Change of Control in compliance with Article 14 of the Amended and
Restated Research and Development Agreement, provided, however, the Licensed Patent Rights and Licensed Know-How shall not be construed, as a result of such assignment, to include any patent rights, know-how, trade secret, and other
intellectual property that, prior to such Change of Control, were owned or Controlled by the Person (other than Licensor) involved in such Change of Control; and (ii) after expiration of the Term without Licensor’s exercise of the Purchase
Option, Symphony Evolution may assign this Agreement to any Person without the prior, written consent of Licensor. Assignment of this Agreement by either Party shall not relieve the assignor of its obligations hereunder. This Agreement shall be
binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. 
  
 8.4. Headings. The descriptive headings contained in this Agreement are for convenience of reference only and shall not affect in any way the
meaning or interpretation of the Agreement. 
  
 8.5.
Independent Contractor. Each Party shall be acting as an independent contractor in performing under this Agreement and shall not be considered or deemed to be an agent, employee, joint venturer or partner of the other Party. 
  
 8.6. Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions
contemplated hereby is not affected in any manner materially adverse to any Party. 
  
 8.7. No Third-Party Beneficiaries. Except with respect to certain indemnification obligations and liability limitations pursuant to ARTICLE 6, nothing in this Agreement, either express or implied, is intended
to or shall confer upon any third party any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. 
  
 8.8. Compliance with Laws. In performing under this Agreement, each Party shall comply with all applicable laws rules and regulations, including
without limitation, the United States Food and Drug Administration and the United States Export Administration Regulations. 
  
 8.9. Amendment. This Agreement may not be amended or modified except by an instrument in writing signed by authorized representatives of Licensor
and Symphony Evolution. 
  
 8.10. Governing Law; Consent to
Jurisdiction and Service of Process. 
  
 (a) This Agreement
shall be governed by, and construed in accordance with, the laws of the State of New York. 
  
 (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of any New York State court or federal 
  

 17 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 court of the United States of America sitting in The City of New York, Borough of Manhattan, and any appellate court from
any jurisdiction thereof, in any action or proceeding arising out of or relating to this Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereby irrevocably and unconditionally agrees that all claims in respect
of any such action or proceeding may be heard and determined in any such New York State court or, to the fullest extent permitted by law, in such federal court. Each of the Parties agrees that a final judgment in any such action or proceeding shall
be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that any Party may otherwise have to bring any action or proceeding relating to
this Agreement. 
  
 (c) Each of the Parties irrevocably and
unconditionally waives, to the fullest extent it may legally and effectively do so, any objection that it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any New York
State or federal court. Each of the Parties hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 
  
 8.11. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO IRREVOCABLY
WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT. 
  
 8.12. Counterparts. This Agreement may be executed in one or more counterparts, and by the respective Parties in
separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same Agreement. 
  
 8.13. No Waiver. The failure of either Party to enforce at any time for any period the provisions of or any rights
deriving from this Agreement shall not be construed to be a waiver of such provisions or rights or the right of such Party thereafter to enforce such provisions. 
  
 SIGNATURES FOLLOW ON NEXT PAGE 
  

 18 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first
written above by their respective duly authorized officers. 
  
  

	
	 SYMPHONY EVOLUTION, INC.

	
	 /s/ Harri V. Taranto


	 Name: Harri V. Taranto
 Title:   Chairman of the Board


  
  

			
	 SYMPHONY EVOLUTION HOLDINGS LLC
  

		
	 By:
	 	 Symphony Capital Partners, L.P.,

	 	 	 its Manager

		
	 By:
	 	 Symphony Capital GP, L.P.,

	 	 	 its general partner

		
	 By:
	 	 Symphony GP, LLC,

	 	 	 its general partner


  

	
	 /s/ Mark Kessel


	 Name: Mark Kessel

	 Title:   Managing Member


  
  

	
	 EXELIXIS, INC.

	
	             /s/ Christoph Pereira


	             Name: Christoph Pereira

	             Title:   Vice President, Legal Affairs and
Secretary


  

 19 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 ANNEX A 
  
 DEFINITIONS 
  
 “$” means United States dollars. 
  
 “Accredited Investor” has the meaning set forth in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as
amended. 
  
 “Act” means the Delaware
Limited Liability Company Act, 6 Del. C. § 18-101 et seq. 
  
 “Additional Funds” has the meaning set forth in Section 2(b) of the Funding Agreement. 
  
 “Additional Funding Date” has the meaning set forth in Section 3 of the Funding Agreement. 
  
 “Additional Party” has the meaning set forth in
Section 12 of the Confidentiality Agreement. 
  
 “Additional Regulatory Filings” means such Governmental Approvals as required to be made under any law applicable to the purchase of the Symphony Evolution Equity Securities under the Agreement. 
  
 “Ad Hoc Meeting” has the meaning set forth in
Paragraph 6 of Annex B to the Amended and Restated Research and Development Agreement. 
  
 “Adjusted Capital Account Deficit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Affected Member” has the meaning set forth in Section 27 of the Investors LLC Agreement.

  
 “Affiliate” means, with respect to any
Person (i) any Person directly or indirectly controlling, controlled by or under common control with such Person, (ii) any officer, director, general partner, member or trustee of such Person, or (iii) any Person who is an officer, director, general
partner, member or trustee of any Person described in clauses (i) or (ii) of this sentence. For purposes of this definition, the terms “controlling,” “controlled by” or “under common control with” shall mean the
possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person or entity, whether through the ownership of voting securities, by contract or otherwise, or the power to elect at least 50% of
the directors, managers, general partners, or persons exercising similar authority with respect to such Person or entities. 
  
 “Amended and Restated Research and Development Agreement” means the Amended and Restated Research and Development Agreement dated
as of June 9, 2005, among Exelixis, Holdings and Symphony Evolution. 
  

 A-1 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Asset Value” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement. 
  
 “Auditors” means an
independent certified public accounting firm of recognized national standing. 
  
 “A Warrant Date” has the meaning set forth in Section 2.04 of the Warrant Purchase Agreement. 
  
 “A Warrants” has the meaning set forth in Section 2.01 of the Warrant Purchase Agreement. 
  
 “A Warrant Shares” has the meaning set forth in
Section 2.01 of the Warrant Purchase Agreement. 
  
 “Bankruptcy Code” means the United States Bankruptcy Code. 
  
 “Bloomberg” means Bloomberg L.P., a multimedia based distributor of information services, including data and analysis for financial markets and businesses. 
  
 “Bloomberg Screen” means the display page designated
on the Bloomberg service (or such other page as may replace that page on that service) for the purpose of displaying prices or bids of Exelixis Common Stock. 
  
 “Business Day” means any day other than Saturday, Sunday or any other day on which commercial banks in The City of New York or the
City of San Francisco are authorized or required by law to remain closed. 
  
 “B Warrants” has the meaning set forth in Section 2.02 of the Warrant Purchase Agreement. 
  
 “B Warrant Date” has the meaning set forth in Section 2.02 of the Warrant Purchase Agreement. 
  
 “B Warrant Shares” has the meaning set forth in
Section 2.05 of the Warrant Purchase Agreement. 
  
 “Capital Contributions” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Capitalized Leases” means all leases that have been or should be, in accordance with GAAP, recorded as capitalized leases.

  
 “Cash Available for Distribution” has
the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Chair” has the meaning set forth in Paragraph 4 of Annex B to the Amended and Restated Research and Development Agreement. 
  

 A-2 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Change of Control” means and includes the occurrence of any of the following
events, but specifically excludes (i) acquisitions of capital stock directly from Exelixis for cash, whether in a public or private offering, (ii) sales of capital stock by stockholders of Exelixis, and (iii) acquisitions of capital stock by or from
any employee benefit plan or related trust: 
  
 (a) the merger, reorganization or consolidation of Exelixis into or with another corporation or legal entity in which Exelixis’ stockholders holding the right to vote with respect to matters generally immediately preceding such merger,
reorganization or consolidation, own less than fifty percent (50%) of the voting securities of the surviving entity; or 
  
 (b) the sale of all or substantially all of Exelixis’ assets or business. 
  
 “Class A Member” means a holder of a Class A
Membership Interest. 
  
 “Class A Membership
Interest” means a Class A Membership Interest in Holdings. 
  
 “Class B Member” means a holder of a Class B Membership Interest. 
  
 “Class B Membership Interest” means a Class B Membership Interest in Holdings. 
  
 “Class C Member” means a holder of a Class C
Membership Interest. 
  
 “Class C Membership
Interest” means a Class C Membership Interest in Holdings. 
  
 “Class D Member” means a holder of a Class D Membership Interest. 
  
 “Class D Membership Interest” means a Class D Membership Interest in Holdings. 
  
 “Clinical Budget” has the meaning set forth in
Section 4.1 of the Amended and Restated Research and Development Agreement. 
  
 “Clinical Plan” has the meaning set forth in Section 4.1 of the Amended and Restated Research and Development Agreement. 
  
 “Closing Date” means June 9, 2005. 
  
 “CMC” means the chemistry, manufacturing and controls documentation as required for filings with
Regulatory Authority relating to the manufacturing, production and testing of drug products. 
  
 “Code” means the Internal Revenue Code of 1986, as amended from time to time. 
  
 “Committed Capital” means $80,000,000.00. 
  
 “Common Stock” means the common stock, par value $0.01 per share, of Symphony Evolution. 

 

 A-3 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Company Expenses” has the meaning set forth in Section 5.09 of the Holdings LLC
Agreement. 
  
 “Company Property” has the
meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Confidential Information” has the meaning set forth in Section 2 of the Confidentiality Agreement. 
  
 “Confidentiality Agreement” means the Confidentiality Agreement, dated as of June 9, 2005, among Symphony Evolution, Holdings,
Exelixis, each Symphony Fund, SCP, SSP, Investors, Symphony Capital, RRD and Daniel F. Hoth, M.D., Herbert J. Conrad, and Alastair J.J. Wood, M.D. 
  
 “Conflict Transaction” has the meaning set forth in Article IX of the Symphony Evolution Charter. 
  
 “Control” means, with respect to any material,
information or intellectual property right, that a Party owns or has a license to such item or right, and has the ability to grant the other Party access, a license or a sublicense (as applicable) in or to such item or right as provided in the
Operative Documents without violating the terms of any agreement or other arrangement with any third party. 
  
 “C Warrants” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
  
 “C Warrant Date” has the meaning set forth in Section
2.06 of the Warrant Purchase Agreement. 
  
 “C Warrant
Shares” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
  
 “Debt” of any Person means, without duplication: 
  
 (a) all indebtedness of such Person for borrowed money, 
  
 (b) all obligations of such Person for the deferred purchase price of property or services (other than any portion of any
trade payable obligation that shall not have remained unpaid for 91 days or more from the later of (A) the original due date of such portion and (B) the customary payment date in the industry and relevant market for such portion), 
  
 (c) all obligations of such Person evidenced by bonds, notes, debentures or
other similar instruments, 
  
 (d) all obligations of such Person
created or arising under any conditional sale or other title retention agreement with respect to property acquired by such Person (whether or not the rights and remedies of the seller or lender under such agreement in an event of default are limited
to repossession or sale of such property), 
  
 (e) all
Capitalized Leases to which such Person is a party, 
  

 A-4 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 (f) all obligations, contingent or otherwise, of such Person under acceptance, letter of credit or
similar facilities, 
  
 (g) all obligations of such Person to
purchase, redeem, retire, defease or otherwise acquire for value any Equity Securities of such Person, 
  
 (h) the net amount of all financial obligations of such Person in respect of Hedge Agreements, 
  
 (i) the net amount of all other financial obligations of such Person under
any contract or other agreement to which such Person is a party, 
  
 (j) all Debt of other Persons of the type described in clauses (a) through (i) above guaranteed, directly or indirectly, in any manner by such Person, or in effect guaranteed, directly or indirectly, by such Person through an agreement (A)
to pay or purchase such Debt or to advance or supply funds for the payment or purchase of such Debt, (B) to purchase, sell or lease (as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of enabling the debtor to
make payment of such Debt or to assure the holder of such Debt against loss, (C) to supply funds to or in any other manner invest in the debtor (including any agreement to pay for property or services irrespective of whether such property is
received or such services are rendered) or (D) otherwise to assure a creditor against loss, and 
  
 (k) all Debt of the type described in clauses (a) through (i) above secured by (or for which the holder of such Debt has an existing right, contingent or
otherwise, to be secured by) any Encumbrance on property (including accounts and contract rights) owned or held or used under lease or license by such Person, even though such Person has not assumed or become liable for payment of such Debt.

  
 “Development Budget” means the budget
for the implementation of the Development Plan that is agreed upon by Exelixis and Symphony Evolution as of the Effective Date, as may be revised from time to time in accordance with the Development Committee Charter and the Amended and Restated
Research and Development Agreement. 
  
 “Development
Committee” has the meaning set forth in Article 3 of the Amended and Restated Research and Development Agreement. 
  
 “Development Committee Charter” has the meaning set forth in Article 3 of the Amended and Restated Research and Development
Agreement. 
  
 “Development Committee
Member” has the meaning set forth in Paragraph 1 of Annex B to the Amended and Restated Research and Development Agreement. 
  
 “Development Plan” means the development plan, covering all the Programs, agreed to by Exelixis and Symphony Evolution as of the
Effective Date, as may be revised from time to time in accordance with the Development Committee Charter and the Amended and Restated Research and Development Agreement. 
  
 “Directors” has the meaning set forth in the Preliminary Statement of the Indemnification Agreement.

  

 A-5 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Disclosing Party” has the meaning set forth in Section 3 of the Confidentiality
Agreement. 
  
 “Discontinuation Closing
Date” means the date of Symphony’s receipt of the Discontinuation Price. 
  
 “Discontinuation Option” has the meaning set forth in Section 11.2(a) of the Amended and Restated Research and Development Agreement. 
  
 “Discontinuation Price” has the meaning set forth in
Section 11.2(a) of the Amended and Restated Research and Development Agreement. 
  
 “Discontinued Program” has the meaning set forth in Section 2.10 of the Novated and Restated Technology License Agreement. 
  
 “Disinterested Directors” has the meaning set forth in Article IX of the Symphony Evolution Charter.

  
 “Distribution” has the meaning set
forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Effective Date” has the meaning set forth in the Novated and Restated Technology License Agreement. 
  
 “Effective Registration Date” has the meaning set forth in the Registration Rights Agreement 
  
 “Encumbrance” means (i) any security interest,
pledge, mortgage, lien (statutory or other), charge or option to purchase, lease or otherwise acquire any interest, (ii) any adverse claim, restriction, covenant, title defect, hypothecation, assignment, deposit arrangement or other encumbrance of
any kind, preference or priority, or (iii) any other security agreement or preferential arrangement of any kind or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement). 
  
 “Enhancements” means findings, improvements,
discoveries, inventions, additions, modifications, enhancements, derivative works, clinical development data, or changes to the Licensed Intellectual Property and Regulatory Files. 
  
 “Equity Securities” means, with respect to any Person, shares of capital stock of (or other
ownership or profit interests in) such Person, warrants, options or other rights for the purchase or other acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, securities convertible
into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or other acquisition from such Person of such shares (or such other interests), and other
ownership or profit interests in such Person (including, without limitation, partnership, member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are authorized or
otherwise existing on any date of determination. 
  

 A-6 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “ERISA” means the United States Employee Retirement Income Security Act of 1974,
as amended. 
  
 “Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 
  
 “Exelixis” means Exelixis, Inc., a Delaware corporation. 
  
 “Exelixis Common Stock” means the common stock, par value $0.001 per share, of Exelixis. 

 
 “Exelixis Common Stock Valuation”
has the meaning set forth in Section 2(e) of the Purchase Option Agreement. 
  
 “Exelixis-GlaxoSmithKline Collaboration Committee” means the committee established by Exelixis and GlaxoSmithKline pursuant to Section 2.2 of the GSK Agreement. 
  
 “Exelixis Member” has the meaning set forth in
Section 2(c) of the Management Services Agreement. 
  
 “Exelixis Obligations” has the meaning set forth in Section 6.1 of the Amended and Restated Research and Development Agreement. 
  

“Exelixis Personnel” has the meaning set forth in Section 8.4 of the Amended and Restated Research and Development Agreement.

  
 “Existing NDA” has the meaning set
forth in Section 2 of the Confidentiality Agreement. 
  
 “Expert” has the meaning set forth in Section 11.2(c) of the Amended and Restated Research and Development Agreement. 
  
 “Extension Funding” has the meaning set forth in Section 2 of the Research Cost Sharing and Extension Agreement. 
  
 “External Directors” has the meaning set forth in the
preamble of the Confidentiality Agreement. 
  
 “FDA” means the United States Food and Drug Administration or its successor agency in the United States. 
  
 “FDA Sponsor” has the meaning set forth in Section 5.1 of the Amended and Restated Research and Development Agreement. 

 
 “Final Purchase Price” has the meaning set forth
in Section 2(j)(ii) of the Purchase Option Agreement. 
  
 “Financial Audits” has the meaning set forth in Section 6.7 of the Amended and Restated Research and Development Agreement. 
  

 A-7 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Financing” has the meaning set forth in the Preliminary Statement of the
Purchase Option Agreement. 
  
 “Fiscal
Year” has for each Operative Document in which it appears the meaning set forth in such Operative Document. 
  
 “Form S-3” means the Registration Form S-3 as defined under the Securities Act. 
  
 “FTE” has the meaning set forth in Section 4.1 of the
Amended and Restated Research and Development Agreement. 
  
 “Funded Capital” has the meaning set forth in Section 2.02(b) of the Warrant Purchase Agreement. 
  
 “Funding Agreement” means the Funding Agreement, dated June 9, 2005, among Exelixis, SCP and Investors. 
  
 “Funding Notice” has the meaning set forth in Section
2(a) of the Funding Agreement. 
  
 “Funds
Price” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “GAAP” means generally accepted accounting principles in effect in the United States of America from time to time. 
  
 “GlaxoSmithKline” means SmithKline Beecham
Corporation, a Pennsylvania corporation, doing business as GlaxoSmithKline. 
  
 “Governmental Approvals” means authorizations, consents, orders, declarations or approvals of, or filings with, or terminations or expirations of waiting periods imposed by any Governmental
Authority. 
  
 “Governmental Authority”
means any United States or non-United States federal, national, supranational, state, provincial, local, or similar government, governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or
arbitral body. 
  
 “Governmental Order”
means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority. 
  
 “GSK Agreement” has the meaning set forth in Section 4.10 of the Novated and Restated Technology License Agreement. 
  
 “Hedge Agreement” means any interest rate swap, cap
or collar agreement, interest rate future or option contract, currency swap agreement, currency future or option contract or other similar hedging agreement. 
  

 A-8 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “HHMI” has the meaning set forth in Annex C of the Novated and Restated
Technology License Agreement. 
  
 “Holdings” means Symphony Evolution Holdings LLC, a Delaware limited liability company. 
  
 “Holdings Claims” has the meaning set forth in Section 5.01 of the Warrant Purchase Agreement. 
  
 “Holdings LLC Agreement” means the Second Amended and
Restated Limited Liability Company Agreement of Holdings dated June 9, 2005. 
  
 “HSR Act Filings” means the premerger notification and report forms required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
  
 “IND” means an Investigational New Drug Application,
as described in 21 U.S.C. § 355(i)(1) and 21 C.F.R. § 312 in the regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof. 
  
 “Indemnification Agreement” means the Indemnification Agreement among Symphony Evolution and the
Directors named therein, dated June 9, 2005. 
  
 “Independent Accountant” has the meaning set forth in Section 2(i)(ii) of the Purchase Option Agreement. 
  
 “Initial Funds” has the meaning set forth in Section 2(a) of the Funding Agreement. 
  
 “Initial Holdings LLC Agreement” means the Agreement
of Limited Liability Company of Holdings, dated March 30, 2005. 
  
 “Initial Investors LLC Agreement” means the Agreement of Limited Liability Company of Investors, dated May 20, 2005. 
  
 “Initial LLC Member” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Interest Certificate” has the meaning set forth in
Section 1.01 of the Holdings LLC Agreement. 
  
 “Interim Holdings LLC Agreement” means the Amended and Restated Agreement of Limited Liability Company of Holdings, dated June 2, 2005. 
  
 “Investment Company Act” means the Investment Company Act of 1940, as amended. 
  
 “Investment Overview” means the investment overview
describing the transactions entered into pursuant to the Operative Documents. 
  

 A-9 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Investment Policy” has the meaning set forth in Section 1(a)(viii) of the
Management Services Agreement. 
  
 “Investors” means Symphony Evolution Investors LLC. 
  
 “Investors LLC Agreement” means Amended and Restated Agreement of Limited Liability Company of Investors dated June 9, 2005. 
  
 “IRS” means the U.S. Internal Revenue Service. 
  
 “Knowledge” means the actual (and not imputed)
knowledge of the executive officers of Exelixis, without the duty of inquiry or investigation. 
  
 “Law” means any law, statute, treaty, constitution, regulation, rule, ordinance, order or Governmental Approval, or other governmental restriction, requirement or determination, of or by any
Governmental Authority. 
  
 “Ledger Fee”
has the meaning set forth in Section 6(b) of the Management Services Agreement. 
  
 “License” has the meaning set forth in the Preliminary Statement of the Purchase Option Agreement. 
  
 “Licensed Intellectual Property” means the Licensed Patent Rights, Symphony Evolution Enhancements, Licensor Enhancements and the
Licensed Know-How. 
  
 “Licensed Know-How”
means any and all proprietary technology (other than the University IP) that is [ * ] 
  
 “Licensed Patent Rights” means:[ * ] 
  
 “Licensor” means Exelixis. 
  
 “Licensor Enhancements” means [ * ] 
  
 “Lien” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Liquidating Event” has the meaning set forth in Section 8.01 of the Holdings LLC Agreement. 
  
 “LLC Agreements” means the Initial Holdings LLC
Agreement, the Interim Holdings LLC Agreement, the Holdings LLC Agreement, the Initial Investors LLC Agreement and the Investors LLC Agreement. 
  
 “Loss” has for each Operative Document in which it appears the meaning set forth in such Operative Document. 
  

 A-10 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Management Budget” has the meaning set forth in Section 4.1 of the Amended and
Restated Research and Development Agreement. 
  
 “Management Fee” has the meaning set forth in Section 6(a) of the Management Services Agreement. 
  
 “Management Plan” has the meaning set forth in Section 4.1 of the Amended and Restated Research and Development Agreement.

  
 “Management Services” has the meaning
set forth in Section 1(a) of the Management Services Agreement. 
  
 “Management Services Agreement” means the Management Services Agreement between Symphony Evolution and RRD, dated as of June 9, 2005. 
  
 “Manager” means (i) for each LLC Agreement in which it appears, the meaning set forth in such LLC
Agreement, and (ii) for each other Operative Document in which it appears, RRD. 
  
 “Manager Event” has the meaning set forth in Section 3.01(f) of the Holdings LLC Agreement. 
  
 “Material Adverse Effect” means, with respect to any Person, a material adverse effect on (i) the business, assets, property or
condition (financial or otherwise) of such Person or, (ii) its ability to comply with and satisfy its respective agreements and obligations under the Operative Documents or, (iii) the enforceability of the obligations of such Person of any of the
Operative Documents to which it is a party. 
  
 “Material Change” has the meaning set forth in Paragraph 12 of Annex B of the Amended and Restated Research and Development Agreement. 
  
 “Material Contract” has the meaning set forth in Section 3(j) of the Management Services Agreement.

  
 “Material Subsidiary” means, at any
time, a Subsidiary of Exelixis having assets in an amount equal to at least 5% of the amount of total consolidated assets of Exelixis and its Subsidiaries (determined as of the last day of the most recent fiscal quarter of Exelixis) or revenues or
net income in an amount equal to at least 5% of the amount of total consolidated revenues or net income of Exelixis and its Subsidiaries for the 12-month period ending on the last day of the most recent fiscal quarter of Exelixis. 
  
 “Maximum Committed Capital” has the meaning set forth
in Section 2.02(b) of the Warrant Purchase Agreement. 
  
 “Medical Discontinuation Event” means (a) as specified in each Protocol, those data that, if collected in such Protocol, demonstrate that such Protocol should not be continued or (b) a series of adverse events, side
effects or other undesirable outcomes that, when collected in a Protocol, would cause a reasonable FDA Sponsor to discontinue such Protocol. 
  

 A-11 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Membership Interest” means (i) for each LLC Agreement in which it appears, the
meaning set forth in such LLC Agreement, and (ii) for each other Operative Document in which it appears, the meaning set forth in the Holdings LLC Agreement. 
  
 “NASDAQ” means the National Association of Securities Dealers Automatic Quotation System. 
  
 “NDA” means a New Drug Application, as defined in the
regulations promulgated by the United States Food and Drug Administration, or any foreign equivalent thereof. 
  
 “Net Debt” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “Non-Exelixis Capital Transaction” means any (i) sale
or other disposition of all or part of the Symphony Evolution Shares or all or substantially all of the operating assets of Symphony Evolution, to a Person other than Exelixis or an Affiliate of Exelixis or (ii) distribution in kind of the Symphony
Evolution Shares following the expiration of the Purchase Option. 
  
 “Novated and Restated Technology License Agreement” means the Novated and Restated Technology License Agreement, dated as of June 9, 2005, among Exelixis, Symphony Evolution and Holdings. 
  
 “Operative Documents” means, collectively, the
Indemnification Agreement, the Holdings LLC Agreement, the Purchase Option Agreement, the Warrant Purchase Agreement, the Registration Rights Agreement, the Subscription Agreement, the Technology License Agreement, the Novated and Restated
Technology License Agreement, the Management Services Agreement, the Research and Development Agreement, the Amended and Restated Research and Development Agreement, the Research Cost Sharing and Extension Agreement, the Confidentiality Agreement,
the Funding Agreement and each other certificate and agreement executed in connection with any of the foregoing documents. 
  
 “Organizational Documents” means any certificates or articles of incorporation or formation, partnership agreements, trust
instruments, bylaws or other governing documents. 
  
 “Parties” means, for each Operative Document or other agreement in which it appears, the parties to such Operative Document or other agreement, as set forth therein (each a “Party”). With
respect to any agreement in which a provision is included therein by reference to a provision in another agreement, the term “Party” shall be read to refer to the parties to the document at hand, not the agreement that is referenced.

  
 “Payment Terms” has the meaning set
forth in Section 8.2 of the Amended and Restated Research and Development Agreement. 
  
 “Percentage” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Permitted Investments” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  

 A-12 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Permitted Investments Letter” means the Permitted Investments Letter dated as of
June 9, 2005, from Symphony Evolution to RRD, as set forth in Exhibit B to the Management Services Agreement. 
  
 “Permitted Lien” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Person” means any individual, partnership (whether
general or limited), limited liability company, corporation, trust, estate, association, nominee or other entity. 
  
 “Personnel” of a Party means such Party, its employees, subcontractors, consultants, representatives and agents. 
  
 “Prime Rate” means the quoted “Prime Rate”
at JPMorgan Chase Bank or, if such bank ceases to exist or is not quoting a base rate, prime rate reference rate or similar rate for United States dollar loans, such other major money center commercial bank in New York City selected by the Manager.

  
 “Product” means any product that
contains or comprises XL647, XL784 or XL999 or any Structurally Related Compound thereof. 
  
 “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Program Option” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development
Agreement. 
  
 “Program Option Closing
Date” has the meaning set forth in Section 11.1(d) of the Amended and Restated Research and Development Agreement. 
  
 “Program Option Exercise Date” has the meaning set forth in Section 11.1(b) of the Amended and Restated Research and
Development Agreement. 
  
 “Program
Option Exercise Notice” has the meaning set forth in Section 11.1(b) of the Amended and Restated Research and Development Agreement. 
  
 “Program Option Exercise Price” has the meaning set forth in Section 11.1(c) of the Amended and Restated Research and Development
Agreement. 
  
 “Program Option
Period” has the meaning set forth in Section 11.1(a) of the Amended and Restated Research and Development Agreement. 
  
 “Programs” means those certain clinical programs pursuing indications for XL647, XL784, and XL999 in accordance with the
Development Plan (each a “Program”). 
  
 “Protocol” means a written protocol that meets the substantive requirements of Section 6 of the ICH Guideline for Good Clinical Practice as adopted by the FDA, effective May 9, 1997 and is included within the
Clinical Plan or later modified or added to the Clinical Plan pursuant to Section 4.2 of the Amended and Restated Research and Development Agreement. 
  

 A-13 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Public Companies” has the meaning set forth in Section 5(e) of the Purchase
Option Agreement. 
  
 “Purchase Option”
has the meaning set forth in Section 1(a) of the Purchase Option Agreement. 
  
 “Purchase Option Agreement” means this Purchase Option Agreement dated as of June 9, 2005, among Exelixis, Holdings and Symphony Evolution. 
  
 “Purchase Option Closing Date” has the meaning set
forth in Section 2(a) of the Purchase Option Agreement. 
  
 “Purchase Option Dispute Notice” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “Purchase Option Exercise Date” has the meaning set forth in Section 2(a) of the Purchase Option Agreement. 
  
 “Purchase Option Exercise Notice” has the meaning set
forth in Section 2(a) of the Purchase Option Agreement. 
  
 “Purchase Option Period” has the meaning set forth in Section 1(c)(iii) of the Purchase Option Agreement. 
  
 “Purchase Price” has the meaning set forth in Section 2(b) of the Purchase Option Agreement. 
  
 “QA Audits” has the meaning set forth in Section 6.6
of the Amended and Restated Research and Development Agreement. 
  
 “Quarterly Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended and Restated Research and Development Agreement. 
  
 “Regents” has the meaning set forth in Section 3.1 of the Novated and Restated Technology License
Agreement. 
  
 “Regents Agreement” has the
meaning set forth in Section 3.1 of the Novated and Restated Technology License Agreement. 
  
 “Regents Claims” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  
 “Regents Indemnitees” has the meaning set forth in Annex C of the Novated and Restated Technology
License Agreement. 
  
 “Regents
Technology” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  

 A-14 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Registration Rights Agreement” means the Registration Rights Agreement dated as
of the Closing Date, between Exelixis and Holdings. 
  
 “Registration Statement” has the meaning set forth in Section 1(b) of the Registration Rights Agreement. 
  
 “Regulatory Authority” means the United States Food and Drug Administration, or any successor agency in the United States, or any
health regulatory authority(ies) in any other country that is a counterpart to the FDA and has responsibility for granting registrations or other regulatory approval for the marketing, manufacture, storage, sale or use of drugs in such other
country. 
  
 “Regulatory Allocation” has
the meaning set forth in Section 3.06 of the Holdings LLC Agreement. 
  
 “Regulatory Files” means any IND, NDA or any other filings filed with any Regulatory Authority with respect to XL647, XL784, XL999 or the Programs. 
  
 “Removed Director” has the meaning set forth in Section 3.01(h)(i) of the Holdings LLC Agreement.

  
 “Representative” of any Person means
such Person’s shareholders, principals, directors, officers, employees, members, managers and/or partners. 
  
 “Research and Development Agreement” means the Research and Development Agreement dated as of June 9, 2005, between Exelixis and
Holdings. 
  
 “Research Cost Sharing and Extension
Agreement” means the Research Cost Sharing and Extension Agreement dated as of June 9, 2005, between Exelixis, Holdings, and Symphony Evolution. 
  
 “RRD” means RRD International, LLC, a Delaware limited liability company. 
  
 “RRD Indemnified Party” has the meaning set forth in
Section 10(a)(i) of the Management Services Agreement. 
  
 “RRD Loss” has the meaning set forth in Section 10(a)(i) of the Management Services Agreement. 
  
 “Schedule K-1” has the meaning set forth in Section 9.02(a) of the Holdings LLC Agreement. 
  
 “Scientific Discontinuation Event” has the meaning
set forth in Section 4.2(f) of the Amended and Restated Research and Development Agreement. 
  
 “SCP” means Symphony Capital Partners, L.P., a Delaware limited partnership. 
  
 “SEC” means the United States Securities and Exchange Commission. 
  

 A-15 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Securities Act” means the Securities Act of 1933, as amended. 
  
 “Shareholder” means any Person who owns any
Symphony Evolution Shares. 
  
 “Solvent”
has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “SSP” means Symphony Strategic Partners, LLC, a Delaware limited liability company. 
  
 “Stock Payment Date” has the meaning set forth in Section 2 of the Subscription Agreement. 
  
 “Stock Purchase Price” has the meaning set forth in
Section 2 of the Subscription Agreement. 
  
 “Structurally Related Compound” means: 
  
 (a) with respect to XL647, any compound that is [ * ] 
  
 (b) with respect to XL784, any compound that is [ * ] 
  
 (c) with respect to XL999, any compound that is [ * ] 
  
 “Subcontracting Agreement” has the meaning set forth
in Section 6.3 of the Amended and Restated Research and Development Agreement. 
  
 “Subcontractor” has the meaning set forth in Section 6.3 of the Amended and Restated Research and Development Agreement. 
  
 “Subscription Agreement” means the Subscription Agreement between Symphony Evolution and Holdings,
dated as of June 9, 2005. 
  
 “Subsidiary”
of any Person means any corporation, partnership, joint venture, limited liability company, trust or estate of which (or in which) more than 50% of (a) the issued and outstanding capital stock having ordinary voting power to elect a majority of the
board of directors of such corporation (irrespective of whether at the time capital stock of any other class or classes of such corporation shall or might have voting power upon the occurrence of any contingency); (b) the interest in the capital or
profits of such partnership, joint venture or limited liability company; or (c) the beneficial interest in such trust or estate is at the time directly or indirectly owned or controlled by such Person, by such Person and one or more of its other
Subsidiaries or by one or more of such Person’s other Subsidiaries. 
  
 “Surviving Entity” means the surviving legal entity which is surviving entity to Exelixis after giving effect to a Change of Control. 
  
 “Symphony Capital” means Symphony Capital LLC, a
Delaware limited liability company. 
  
 “Symphony
Evolution” means Symphony Evolution, Inc., a Delaware corporation. 
  

 A-16 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Symphony Evolution Board” means the Symphony Evolution board of directors.

  
 “Symphony Evolution By-laws” means the
By-laws of Symphony Evolution, as adopted by resolution of the Symphony Evolution Board on June 9, 2005. 
  
 “Symphony Evolution Charter” means the Amended and Restated Certificate of Incorporation of Symphony Evolution, dated as of June
9, 2005. 
  
 “Symphony Evolution Director
Event” has the meaning set forth in Section 3.01(h)(i) of the Holdings LLC Agreement. 
  
 “Symphony Evolution Enhancements” means [ * ] 
  
 “Symphony Evolution Equity Securities” means the Common Stock and any other stock or shares issued by Symphony Evolution.

  
 “Symphony Evolution Loss” has the
meaning set forth in Section 10(b) of the Management Services Agreement. 
  
 “Symphony Evolution Securities Encumbrance” has the meaning set forth in Section 4(b)(ii) of the Purchase Option Agreement. 
  
 “Symphony Evolution Shares” has the meaning set forth in Section 2.02 of the Holdings LLC Agreement.

  
 “Symphony Funds” means Symphony
Capital Partners, L.P., a Delaware limited partnership, and Symphony Strategic Partners, LLC, a Delaware limited liability company (each a “Symphony Fund”). 
  
 “Symphony Member” has the meaning set forth in Section 4.2(d) of the Amended and Restated Research
and Development Agreement. 
  
 “Tangible
Materials” means [ * ]. 
  
 “Tax
Amount” has the meaning set forth in Section 4.02 of the Holdings LLC Agreement. 
  
 “Technology License Agreement” means the Technology License Agreement, dated as of June 9, 2005, between Exelixis and Holdings. 
  
 “Term” means the period starting on the Closing Date and ending upon the termination or expiration
of the Purchase Option Period. 
  
 “Territory” means the world. 
  
 “Third Party IP” has the meaning set forth in Section 2.9 of the Novated and Restated Technology License Agreement. 
  

 A-17 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Third Party Licensor” means (a) a third party from which Exelixis has received a
license or sublicense to Licensed Intellectual Property or (b) a third party to which Exelixis has granted a license or sublicense to the Licensed Intellectual Property. As of the Closing Date, GlaxoSmithKline is the only Third Party Licensor.

  
 “Transfer” has for each Operative
Document in which it appears the meaning set forth in such Operative Document. 
  
 “Transferee” has, for each Operative Document in which it appears, the meaning set forth in such Operative Document. 
  
 “University Agreements” has the meaning set forth in Section 3.1 of the Novated and Restated
Technology License Agreement. 
  
 “University
IP” has the meaning set forth in Section 3.1 of the Novated and Restated Technology License Agreement. 
  
 “Voluntary Bankruptcy” has the meaning set forth in Section 1.01 of the Holdings LLC Agreement. 
  
 “Warrant Closing” has the meaning set forth in
Section 2.07 of the Warrant Purchase Agreement. 
  
 “Warrant Date” has the meaning set forth in Section 2.06 of the Warrant Purchase Agreement. 
  
 “Warrant Purchase Agreement” means the Warrant Purchase Agreement dated as of the Closing Date, between Exelixis and Holdings.

  
 “Warrants” has the meaning set forth
in Section 2.03 of the Warrant Purchase Agreement. 
  
 “Warrant Share Legend” has the meaning set forth in Section 6.02 of the Warrant Purchase Agreement. 
  
 “Warrant Shares” has the meaning set forth in Section 2.03 of the Warrant Purchase Agreement. 
  
 “XL647” means: [ * ] 
  
 “XL784” means: [ * ] 
  
 “XL999” means: [ * ] 
  
 “Yale” has the meaning set forth in Section 3.1 of
the Novated and Restated Technology License Agreement. 
  

 A-18 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 “Yale Agreement” has the meaning set forth in Section 3.1 of the Novated and
Restated Technology License Agreement. 
  
 “Yale
Claims” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  
 “Yale Indemnitees” has the meaning set forth in Annex C of the Novated and Restated Technology License Agreement. 
  
 “Yale Technology” has the meaning set forth in Annex
C of the Novated and Restated Technology License Agreement. 
  

 A-19 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 ANNEX B 
  
 PATENTS INCLUDED IN LICENSED PATENT RIGHTS 
  
 [ * ] 
  

 B-1 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 








 ANNEX C 
  
 SUBLICENSE TERMS 
  
 [ * ] 
  

 C-1 
  


 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED
AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.